<DOC>
	<DOCNO>NCT01024387</DOCNO>
	<brief_summary>The purpose research study determine effectiveness AMG 479 carcinoid pancreatic neuroendocrine tumor . AMG 479 antibody make laboratory . Antibodies highly specific protein produce body 's immune system recognize foreign substance teh body . AMG 479 use research study information research study suggest AMG 479 may help prevent growth neuroendocrine tumor .</brief_summary>
	<brief_title>AMG 479 Advanced Carcinoid Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>- Participants receive treatment AMG 479 every three week ( 1 cycle 3 week ) . AMG 479 give intravenous infusion . - At begin every cycle , participant follow procedure : medical history , physical exam , blood test electrocardiogram ( EKG ) . - Following every 3 cycle , participant follow procedure : blood test , assessment tumor CT scan MRI 24-hour urine sample ( applicable ) . - Participants may remain research study long doctor determines show evidence clinical benefit treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Locally unresectable metastatic carcinoid pancreatic neuroendocrine tumor . To classified pancreatic neuroendocrine tumor , patient must clinical evidence currently primary pancreatic neuroendocrine lesion . Measurable disease RECIST criterion Evidence progressive disease ( RECIST ) within 12 month study entry . Tumors must consider well moderatelydifferentiated . Patients poorly differentiate neuroendocrine carcinoma small cell carcinoma exclude study . Adequate hepatic , renal , bone marrow glycemic function outline protocol Prior treatment chemotherapy , hepatic artery embolization , surgery therapeutic agent allow . Prior concurrent therapy somatostatin analog permit : however patient must continue stable dose somatostatin analog receive study treatment . 18 year age old ECOG performance status 0 , 1 , 2 Life expectancy least 12 week Negative pregnancy test Ability sign inform consent Poorly differentiate small cell neuroendocrine carcinoma Insulin secrete pancreatic neuroendocrine tumor ( insulinomas ) Clinically apparent central nervous system metastases carcinomatous meningitis . Myocardial infraction past 6 month Major surgery 4 week prior enrollment Uncontrolled serious medical psychiatric illness Pregnant lactate woman . Both men woman childbearing potential must advise importance use effective birth control measure course study . Prior antitumor therapy within 4 week enrollment ( exception somatostatin analog ) . Recent infection require systemic antiinfective treatment complete 14 day less prior enrollment ( exception uncomplicated urinary tract infection upper respiratory tract infection ) . Known positive test human immunodeficiency virus , hepatitis C , chronic active hepatitis B Prior IGF IGF receptor inhibitor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>AMG 479</keyword>
</DOC>